BRIEF-Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China
Reuters
Feb 09
BRIEF-Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China
Feb 8 (Reuters) - Biogen BIIB.O:
BIOGEN: BIOLOGICS LICENSE APPLICATION FOR SUBCUTANEOUS FORMULATION OF LEQEMBI FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE DESIGNATED FOR PRIORITY REVIEW IN CHINA
Source text: https://tinyurl.com/ye2b3au3
Further company coverage: 4523.T
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.